1例血小板减少合并急性冠脉综合征患者抗血小板治疗的分析
2023-08-03张新乐张伟霞
张新乐 张伟霞


摘 要 目的: 探讨血小板减少合并急性冠脉综合征患者抗血小板药物的应用。方法: 对 1例血小板减少症患者发生急性冠脉综合征的诊治过程分析讨论,查阅相关文献,总结此类病例抗血小板治疗情况。结果与结论: 合并血小板减少的患者发生急性冠脉综合征时进行抗血小板治疗安全性较好,在平衡出血和栓塞的风险以后,尽可能长期行抗血小板治疗。
关键词 急性冠脉综合征 血小板减少 抗血小板药物
中图分类号:R541.4; R973.2 文献标志码:B 文章编号:1006-1533(2023)11-0071-04
引用本文 张新乐, 张伟霞. 1例血小板减少合并急性冠脉综合征患者抗血小板治疗的分析[J]. 上海医药, 2023, 44(11): 71-74.
Analysis of antiplatelet therapy in a patient with thrombocytopenia and acute coronary syndrome
ZHANG Xinle1, ZHANG Weixia2
(1. Department of Pharmacy, the Seventh Peoples Hospital of Zhengzhou, Zhengzhou 450016, China; 2. Department of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China)
ABSTRACT Objective: To discuss the application of antiplatelet therapy in acute coronary syndrome patient with thrombocytopenia. Methods: The therapy for this patient was analyzed and discussed, and the antiplatelet therapy in such cases was summarized based on the related literatures. Results & Conclusion: Antiplatelet therapy is safer in patients with acute coronary syndromes complicated with thrombocytopenia and should be carried out for as long as possible after balancing the risk of bleeding and embolism.
KEY WORDS acute coronary syndrome; thrombocytopenia; antiplatelet therapy
急性冠脉综合征(acute coronary syndrome, ACS)作为冠状动脉粥样硬化性心脏病一种危急表现类型,是全球致病及致死的主要元凶之一[1]。在疾病的发生发展过程中,血小板的聚集起着尤为关键的作用。因此,抗血小板是治疗的基石,ACS患者需要抗血小板治疗来预防血栓栓塞引发的缺血风险,然而,血小板减少症患者容易发生出血的风险。目前,对于ACS合并血小板减少患者抗栓方案还没有指导性的指南或者共识,更多的是经验性的个案报道。本文报道临床药师参与1例急性心肌梗死伴血小板减少患者的病例分析,以期为急性冠脉综合征伴血小板减少患者的抗栓治疗提供参考。
1 病例资料
患者,男,60岁,2022年1月10日劳累后出现心前区闷痛,伴左臂放射痛,持续约15 min,休息后缓解。患者每日活动后或情绪激动时均有胸痛,性质同前述。……
